Cargando…

Inflammatory markers in autoimmunity induced by checkpoint inhibitors

PURPOSE: Immune checkpoint inhibitors (ICI) are highly effective in several cancer entities, but also invoke a variety of immune-related adverse events (irAE). These are mostly reversible, but can be life-threatening or even fatal. Currently, the pathogenesis is not fully understood, but crucial for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Husain, Beate, Kirchberger, Michael Constantin, Erdmann, Michael, Schüpferling, Sabine, Abolhassani, Amir-Reza, Fröhlich, Waltraud, Berking, Carola, Heinzerling, Lucie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article – Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076116/ https://www.ncbi.nlm.nih.gov/pubmed/33837821 http://dx.doi.org/10.1007/s00432-021-03550-5

Ejemplares similares

Therapy preferences in melanoma treatment—Willingness to pay and preference of quality versus length of life of patients, physicians, healthy individuals and physicians with oncological disease
por: Weiss, Julia, et al.
Publicado: (2020)

The Role of Immune Checkpoint Blockade in Uveal Melanoma
por: Wessely, Anja, et al.
Publicado: (2020)

“I Feel I’m in Best Hands with You!”: A Survey of Patient Satisfaction in a German University Skin Cancer Centre
por: STEEB, Theresa, et al.
Publicado: (2021)

Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients
por: Kirchberger, Michael Constantin, et al.
Publicado: (2018)

Tirbanibulin 1% Ointment Significantly Reduces the Actinic Keratosis Area and Severity Index in Patients with Actinic Keratosis: Results from a Real-World Study
por: Kirchberger, Michael Constantin, et al.
Publicado: (2023)

Experiences of In-Patients with Skin Cancer in a German University Hospital Setting: A Cross-Sectional Survey
por: Steeb, Theresa, et al.
Publicado: (2021)

Eosinophil-cationic protein - a novel liquid prognostic biomarker in melanoma
por: Krückel, Annika, et al.
Publicado: (2019)

Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG
por: Knispel, Sarah, et al.
Publicado: (2020)

Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study
por: Heppt, Markus V., et al.
Publicado: (2019)

BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation
por: Hoyer, Stefanie, et al.
Publicado: (2021)

Electrocardiographic features of immune checkpoint inhibitor associated myocarditis
por: Zlotoff, Daniel A, et al.
Publicado: (2021)

Checkpoint-inhibitor induced Polyserositis with Edema
por: Zierold, Sarah, et al.
Publicado: (2022)

Health-related quality of life (EuroQol 5D-5L) in patients with autoimmunity in the context of immunotherapy: A large dataset comprising cancer patients after cessation of checkpoint inhibitor therapy and patients with autoimmune diseases
por: Schulz, Thomas U., et al.
Publicado: (2022)

Conventional and three-dimensional photography as a tool to map distribution patterns of in-transit melanoma metastases on the lower extremity
por: Müller, Kilian, et al.
Publicado: (2023)

Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
por: Yin, Xiaoqiang, et al.
Publicado: (2022)

The role of IFN-γ-signalling in response to immune checkpoint blockade therapy
por: Wong, Chun Wai, et al.
Publicado: (2023)

The Quality of Practice Guidelines for Melanoma: A Methodologic Appraisal with the AGREE II and AGREE-REX Instruments
por: Steeb, Theresa, et al.
Publicado: (2020)

T-cell response to checkpoint blockade immunotherapies: from fundamental mechanisms to treatment signatures
por: Elliot, Thomas A.E., et al.
Publicado: (2023)

Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study
por: Martinez Chanza, Nieves, et al.
Publicado: (2020)

Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer
por: Shao, Jun, et al.
Publicado: (2020)

Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma
por: Krebs, Franziska K., et al.
Publicado: (2021)

Steroid-Refractory Immune-Related Adverse Events Induced by Checkpoint Inhibitors
por: Tomsitz, Dirk, et al.
Publicado: (2023)

Malignant Tumours Presenting as Chronic Leg or Foot Ulcers
por: Toussaint, Frédéric, et al.
Publicado: (2021)

Autoimmune diseases and immunosuppressive therapy in relation to the risk of glioma
por: Anssar, Tareq M., et al.
Publicado: (2019)

Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition
por: Rogiers, Aljosja, et al.
Publicado: (2021)

Increased rates of immunosuppressive treatment and hospitalization after checkpoint inhibitor therapy in cancer patients with autoimmune disease
por: Bender, David Andrew, et al.
Publicado: (2020)

Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors
por: Rezasoltani, Sama, et al.
Publicado: (2020)

Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists
por: Illouz, Frédéric, et al.
Publicado: (2017)

Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients
por: Leiter, Ulrike, et al.
Publicado: (2020)

Activation Markers on B and T Cells and Immune Checkpoints in Autoimmune Rheumatic Diseases
por: Gerasimova, Elena V., et al.
Publicado: (2022)

Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events
por: Coukos, Alexander, et al.
Publicado: (2022)

Unusual presentation of a cutaneous metastasis in the face arising from gastric cancer: a case report
por: Kirchberger, Michael Constantin
Publicado: (2018)

Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease
por: Alexander, Swetha, et al.
Publicado: (2021)

Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports
por: Schliep, Stefan, et al.
Publicado: (2018)

Systemic inflammation markers and cancer incidence in the UK Biobank
por: Nøst, Therese Haugdahl, et al.
Publicado: (2021)

Serum markers change for intraocular metastasis in renal cell carcinoma
por: Sun, Tie, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in the Treatment of Breast Cancer Brain Metastases
por: Schlam, Ilana, et al.
Publicado: (2022)

Screening of immunosuppressive cells from colorectal adenocarcinoma and identification of prognostic markers
por: Li, Fazhan, et al.
Publicado: (2021)

Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?
por: Wessely, Anja, et al.
Publicado: (2020)

Checkpoint blockade‐based immunotherapy in the context of tumor microenvironment: Opportunities and challenges
por: Duan, Jingjing, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_n05gtgcjr4i0obo4hcplu8ej51